Dapagliflozin: a review of its use in type 2 diabetes mellitus.
about
Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsNovel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trialPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Dapagliflozin: a review of its use in patients with type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Combination therapy for type 2 diabetes: dapagliflozin plus metformin.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.SGLT2 Inhibitors: Benefit/Risk Balance.Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Renal Effects of Antisense-Mediated Inhibition of SGLT2.Dapagliflozin for prednisone-induced hyperglycemia in acute exacerbation of chronic obstructive pulmonary disease.The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
P2860
Q28072765-6529240D-343D-46DC-9FD1-EB7BBF69AFFDQ33771405-2E016C2A-751F-4005-A953-9D08444A1A50Q33885732-6FBF0DE2-7B33-4FCC-9007-3AC0781AE3CEQ34161881-7BD4B50D-0117-4927-8FAD-B93058ABB9DAQ34397646-041540EC-1E5B-4F60-B4A2-CCC4987CA9FAQ35194026-19AC51DD-8EE9-4C70-A815-C91590BFA355Q35973288-A3536346-1011-4726-A841-912153CAE7C4Q36179371-383D5E92-2E26-4451-AFDC-7FF774BC290EQ37524302-064A0A06-CCAE-4FB8-BE22-43ABF41786C0Q37729725-31AA5E28-3384-4EDA-B7C4-3BDF359EB6ABQ37736727-724ECD42-237C-4C86-A213-0CBC11FC5D8BQ38086611-83B73C61-D4AF-43BE-8151-44B4AD92DDF9Q38130748-138C5943-5EE4-4125-BA59-B8237EE48204Q38175467-6FD5B310-65F6-46CA-A3F5-0C2F3E18A5CFQ38177173-2B86239C-FFB8-4BA3-9839-A4B3DD8B4B28Q38199526-A22D1175-4D0D-4857-9321-37CC39D5FC27Q38212007-B085F758-0727-499F-9112-3B0BED962679Q38267346-2F89FA40-9B44-4627-8A1A-9330335A21FFQ38389823-BAA70BAE-25D8-4BBC-A637-684AF09684F8Q38619164-96D32952-FAC5-4A78-B6A5-656AC95E4B10Q38633198-60E03C8E-ABF3-46C5-8B98-4F01BF1B587DQ38845574-CF6BDBE8-AA8D-4943-867B-3B95732BA278Q38931842-CC56D037-B695-4843-AA22-C6BD858DDD8FQ44757675-DECE4D9C-7638-4FD8-9304-20D1DA330B84Q46207930-8B2B2439-A95C-41D4-8EDC-C28628CB5B6DQ46492279-43AC2A74-FD1B-40EB-8DAA-BA94A183AC83Q47189286-4656D8AE-97BC-4D56-9AE8-17EF0D0D9CC4Q47261527-A970F4AA-3D21-4047-ACB4-162800D40392Q51679305-13DD36BA-FBBA-458A-81D9-DC9D897FECE1
P2860
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@ast
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@en
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@nl
type
label
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@ast
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@en
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@nl
prefLabel
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@ast
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@en
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@nl
P1433
P1476
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
@en
P304
P356
10.2165/11209910-000000000-00000
P577
2012-12-01T00:00:00Z
P6179
1033830329